The Director-General of the Indian Council of Medical Research (ICMR), Dr. Rajiv Bahl, has emphasised a number of preventive measures meant to stop the spread of the Nipah virus in the face of a constant threat. He claims that these precautions are similar to those used against COVID-19, such as frequent handwashing and the wearing of masks.
However, because first instances of the disease frequently spread the virus to others, limiting contact with infected people is the main concern in the case of Nipah.
Dr. Bahl also emphasised the crucial necessity for biosafety, hospital safety, and isolation while underlining the significance of preventing exposure to bodily fluids and blood.
India Is Procuring 20 Doses Of Monoclonal Antibody: ICMR DG
When you look at the Nipah virus’s fatality rate, you can see how dangerous it is. According to Dr. Bahl, there is a striking difference between Nipah and COVID-19 cases, with the former having a fatality rate between 40% and 70%, greatly exceeding the relatively lower mortality rate of 2% to 3% recorded in COVID-19 cases.
“We got some doses of monoclonal antibody from Australia in 2018. Currently, the doses are available for only 10 patients,” he said. “Twenty more doses are being procured. But the medicine needs to be given during the early stage of the infection,” he added.
Regarding the availability of monoclonal antibody doses, the ICMR director disclosed that at the moment, India has only ten patients’ worth of doses available. He said that none have yet been used in treatment while letting India know that 20 further doses of monoclonal antibody are being ordered.
Dr. Bahl guarantees that despite the difficulties brought on by the Nipah outbreak, actions are being taken to stop the virus’s spread.
Also Read: ABC sends Chandrababu Naidu to 14-day judicial remand in corruption case
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK
